← Product Code [DDG](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DDG) · K053075

# N ANTISERA TO HUMAN TRANSFERRIN (K053075)

_Dade Behring, Inc. · DDG · Mar 16, 2006 · Immunology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DDG/K053075

## Device Facts

- **Applicant:** Dade Behring, Inc.
- **Product Code:** [DDG](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DDG.md)
- **Decision Date:** Mar 16, 2006
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 866.5880
- **Device Class:** Class 2
- **Review Panel:** Immunology

## Indications for Use

In vitro diagnostic reagents for the quantitative determination of transferrin in human serum, heparinized and EDTA plasma, as well as transferrin in human urine by means of immunonephelometery on the BN™ Systems.

## Device Story

N Antisera to Human Transferrin is an in vitro diagnostic reagent kit used on BN™ Systems. It detects transferrin in human serum, plasma, or urine samples. Principle of operation: immunonephelometry; proteins in sample form immune complexes with specific antibodies; complexes scatter light beam; scattered light intensity is proportional to protein concentration. Result is determined by comparing intensity against a standard of known concentration. Used in clinical laboratory settings by trained personnel. Output provides quantitative transferrin levels to assist clinicians in diagnosing malnutrition, inflammation, infection, and anemia.

## Clinical Evidence

No clinical studies performed. Evidence consists of analytical performance data including matrix comparison studies and interference testing. Matrix comparison (N=40-99 per group) showed high correlation (R² 0.9851-0.9936) between serum and plasma samples. Interference testing confirmed no significant interference from bilirubin, hemoglobin, triglycerides, or heparin anticoagulants.

## Technological Characteristics

Quantitative immunonephelometry assay. Reagents: polyclonal rabbit anti-human transferrin antiserum. Instrumentation: BN™ Systems (BNII, BN 100, BN Prospec). Detection principle: light scattering intensity proportional to protein concentration. Sample matrices: serum, heparinized plasma, EDTA plasma, urine.

## Regulatory Identification

A transferrin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the transferrin (an iron-binding and transporting serum protein) in serum, plasma, and other body fluids. Measurement of transferrin levels aids in the diagnosis of malnutrition, acute inflammation, infection, and red blood cell disorders, such as iron deficiency anemia.

## Predicate Devices

- N Antisera to Human Transferrin (k972840)

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number:
k053075

B. Purpose for Submission:
Device modification. Addition of heparinized and EDTA plasmas as sample matrices for both human transferrin and haptoglobin (note: haptoglobin is Class II exempt)

C. Measurand:
Human transferring and human haptoglobin

D. Type of Test:
Quantitative immunonephelometry

E. Applicant:
Dade Behring, Inc.

F. Proprietary and Established Names:
N Antisera to Human Transferrin, Transferrin immunological test system
N Antisera to Human Haptoglobin, Haptoglobin immunological test system

G. Regulatory Information:
1. Regulation section:
21 CFR 866.5880, Transferrin immunological test system
21 CFR 866.5460, Haptoglobin immunological test system
2. Classification:
Class II (Transferrin)
Class II (Haptoglobin)
3. Product code:
DDG, Transferrin, antigen, antiserum, control
DAD, Haptoglobin, antigen, antiserum, control
4. Panel:
Immunology 82

H. Intended Use:
1. Intended use(s):
In vitro diagnostic reagents for the quantitative determination of transferrin and haptoglobin in human serum, heparinized and EDTA plasma, as well as transferrin in human urine by means of immunonephelometry on the BN™ systems.
2. Indication(s) for use:
In vitro diagnostic reagents for the quantitative determination of transferrin in human serum, heparinized and EDTA plasma, as well as transferrin in human urine by means of immunonephelometry on the BN™ Systems. Measurement of transferrin levels aids in the diagnosis of malnutrition, acute inflammation, infection, and red blood cell disorders, such as iron deficiency anemia.
3. Special conditions for use statement(s):
For prescription use only.
4. Special instrument requirements:
For use on the Dade Behring BNII, BN 100, and BN Prospec analyzers,

{1}

previously cleared under k860894.

I. Device Description:
The device consists of one vial containing 2 ml of N antiserum to human transferrin.

J. Substantial Equivalence Information:
1. Predicate device name(s):
N Antisera to Human Transferrin
2. Predicate 510(k) number(s):
k972840
3. Comparison with predicate:

|  Similarities  |   |   |
| --- | --- | --- |
|  Item | Device | Predicate  |
|  Intended Use | In vitro diagnostic reagents for the quantitative determination of transferrin and haptoglobin in human serum, heparinized and EDTA plasma, as well as transferrin in human urine by means of immunonephelometry on the BN™ systems. | In vitro diagnostic reagents for the quantitative determination of transferrin and haptoglobin in human serum, as well as transferrin in human urine by means of immunonephelometry on the BN™ systems.  |
|  Antibody | Rabbit anti-Human transferrin (polyclonal) | Same  |
|  Instrumentation | BN™ Systems | Same  |
|  Assay Format | Quantitative nephelometry | Same  |
|  Differences  |   |   |
| --- | --- | --- |
|  Item | Device | Predicate  |
|  Sample | Serum, heparinized and EDTA plasma, urine | Serum and urine  |

K. Standard/Guidance Document Referenced (if applicable):
None

L. Test Principle:
Proteins contained in human body fluids form immunochemical reaction with specific antibodies. These complexes scatter a beam o flight passed through the sample. The intensity of the scattered light is proportional to the concentration of the relevant protein in the sample. The result is evaluated by comparison with a standard of known concentration.

M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
No change.
b. Linearity/assay reportable range:
No change.

{2}

c. Traceability, Stability, Expected values (controls, calibrators, or methods): No change.

d. Detection limit: No change.

e. Analytical specificity: Interference by endogenous substances

Transferrin: Normal serum samples (2.14-3.17 g/L) were spiked with increasing concentrations of bilirubin, hemoglobin, and triglycerides. The percent recovery was determined for each sample relative to a reference sample (± 20%). No interference was seen up to: 0.6 g/L bilirubin, 8.2 g/L triglycerides and 10 g/L hemoglobin. Normal serum samples (2.17-2.94 g/L) were compared to sera spiked with 5% of lithium, sodium, or ammonium heparin to determine potential interference by heparin anticoagulants for plasma samples. No interference was seen. Percent deviation (± 7%) between the mean recoveries of the heparin types was (-)1.06 to (+)0.528%.

Haptoglobin: No data was provided for interference from bilirubin, hemoglobin, or triglycerides. Normal serum samples (0.6-2.11 g/L) were compared to sera spiked with 5% of lithium, sodium, or ammonium heparin to determine potential interference by heparin anticoagulants for plasma samples. No interference was seen. Percent deviation (± 7%) between the mean recoveries of the heparin types was (-)1.59 to (+)0.403%.

f. Assay cut-off: No change.

2. Comparison studies:

a. Method comparison with predicate device: Not applicable.

b. Matrix comparison: Fresh and/or frozen serum and plasma samples, covering the reportable range (1:20 dilutions, Transferrin: 0.35-5.6 g/L; Haptoglobin: 0.26-8.3 g/L) were compared to determine if any significant bias existed between matrices. The heparin samples were a mixture of heparin types, however since the percent deviation between the heparin types (see Interference studies above) was low, this was deemed acceptable.

|   | N (pooled) | Regression equation | R² | 95% Confidence intervals (slope)  |
| --- | --- | --- | --- | --- |
|  Transferrin |  |  |  |   |
|  Heparin | 99 | y = 0.9768x - 0.0204 | 0.9851 | 0.9499, 1.003  |
|  EDTA | 40 | y = 1.0067x - 0.0508 | 0.9916 | 0.9767, 1.0425  |
|  Haptoglobin |  |  |  |   |
|  Heparin | 79 | y = 0.9777x - 0.0095 | 0.9932 | 0.9579, 1.0037  |
|  EDTA | 47 | y = 0.9963x - 0.0208 | 0.9936 | 0.9799, 1.0180  |

3. Clinical studies:

a. Clinical Sensitivity: No change.

{3}

b. Clinical specificity:
No change.

4. Clinical cut-off:
No change.

5. Expected values/Reference range:
No change.

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

4

---

**Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DDG/K053075](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DDG/K053075)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com